



ASX announcement

SciGen clarifies Conditional Agreement from Bioton S.A.

Singapore. Monday 28 November 2005. SciGen Limited (ASX: SIE) wishes to clarify the notification lodged this morning pertaining to the Conditional Agreement for Polish biopharmaceutical company Bioton S.A. to acquire the shares of the company.

1. The notification by Bioton was a requirement of the Singapore Securities Commission to demonstrate Bioton's ability to fund the acquisition **IF** SciGen shareholders decide to accept the Offer;
2. Bioton will be required to lodge a Prospectus to support the Offer to acquire shares in SciGen. This is expected early in 2006;
3. The Board of SciGen is seeking an independent advice on the Bioton Offer and will make this available to shareholders;
4. SciGen shareholders will have three options:
 - a. Reject the Offer by Bioton and remain as shareholders in SciGen;
 - b. Accept the Offer by Bioton to acquire shares for A\$075;
 - c. Accept the Offer by Bioton to exchange SIE shares for Bioton shares for 7.4 Zlote

Bioton has publicly disclosed that it wishes SciGen to remain a publicly listed company on the ASX. This intention is supported by the Board of SciGen.

The Offer to acquire shares is mandatory under takeover rules with the Singapore Securities Commission. This rule was triggered following Bioton's agreement to acquire the shares of the second largest investor in SciGen, SciTech Genetics taking its equity from 25.6% to 44.7%.